Team Genome and Cancer, Hematology Laboratory Assistance Publique-Hopitaux de Paris, Saint-Louis Hospital, Paris, France.
Blood. 2011 Apr 14;117(15):e161-70. doi: 10.1182/blood-2010-09-308726. Epub 2011 Feb 16.
Fanconi anemia (FA) is a genetic condition associated with bone marrow (BM) failure, myelodysplasia (MDS), and acute myeloid leukemia (AML). We studied 57 FA patients with hypoplastic or aplastic anemia (n = 20), MDS (n = 18), AML (n = 11), or no BM abnormality (n = 8). BM samples were analyzed by karyotype, high-density DNA arrays with respect to paired fibroblasts, and by selected oncogene sequencing. A specific pattern of chromosomal abnormalities was found in MDS/AML, which included 1q+ (44.8%), 3q+ (41.4%), -7/7q (17.2%), and 11q- (13.8%). Moreover, cryptic RUNX1/AML1 lesions (translocations, deletions, or mutations) were observed for the first time in FA (20.7%). Rare mutations of NRAS, FLT3-ITD, MLL-PTD, ERG amplification, and ZFP36L2-PRDM16 translocation, but no TP53, TET2, CBL, NPM1, and CEBPα mutations were found. Frequent homozygosity regions were related not to somatic copy-neutral loss of heterozygosity but to consanguinity, suggesting that homologous recombination is not a common progression mechanism in FA. Importantly, the RUNX1 and other chromosomal/genomic lesions were found at the MDS/AML stages, except for 1q+, which was found at all stages. These data have implications for staging and therapeutic managing in FA patients, and also to analyze the mechanisms of clonal evolution and oncogenesis in a background of genomic instability and BM failure.
范可尼贫血(FA)是一种与骨髓(BM)衰竭、骨髓增生异常综合征(MDS)和急性髓系白血病(AML)相关的遗传疾病。我们研究了 57 例患有低增生性或再生障碍性贫血(n = 20)、MDS(n = 18)、AML(n = 11)或无 BM 异常(n = 8)的 FA 患者。通过核型分析、针对配对成纤维细胞的高密度 DNA 微阵列以及选定的癌基因测序对 BM 样本进行了分析。在 MDS/AML 中发现了一种特定的染色体异常模式,包括 1q+(44.8%)、3q+(41.4%)、-7/7q(17.2%)和 11q-(13.8%)。此外,首次在 FA 中观察到隐匿性 RUNX1/AML1 病变(易位、缺失或突变)(20.7%)。罕见的 NRAS、FLT3-ITD、MLL-PTD、ERG 扩增和 ZFP36L2-PRDM16 易位突变,但无 TP53、TET2、CBL、NPM1 和 CEBPα 突变。频繁的纯合子区域与体细胞拷贝中性杂合性丢失无关,而是与近亲结婚有关,这表明同源重组不是 FA 中常见的进展机制。重要的是,RUNX1 和其他染色体/基因组病变在 MDS/AML 阶段发现,除了 1q+在所有阶段都发现。这些数据对 FA 患者的分期和治疗管理具有重要意义,并且还可以分析在基因组不稳定性和 BM 衰竭背景下克隆进化和致癌的机制。